Aimmune Therapeutics Inc (AIMT) Receives $52.56 Average Price Target from Brokerages

Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) have been assigned an average recommendation of “Buy” from the twelve analysts that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $52.56.

AIMT has been the subject of a number of analyst reports. ValuEngine downgraded shares of Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 7th. Cantor Fitzgerald set a $62.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Monday, October 15th. BidaskClub downgraded shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 11th. Stifel Nicolaus initiated coverage on shares of Aimmune Therapeutics in a research note on Thursday, September 13th. They set a “hold” rating and a $33.00 target price for the company. Finally, Roth Capital set a $80.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 9th.

AIMT stock traded up $2.04 during trading on Friday, reaching $30.29. The company had a trading volume of 607,251 shares, compared to its average volume of 632,111. Aimmune Therapeutics has a 52 week low of $24.56 and a 52 week high of $42.00. The company has a market cap of $1.77 billion, a P/E ratio of -11.61 and a beta of -0.10.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.03. As a group, equities research analysts anticipate that Aimmune Therapeutics will post -3.64 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in AIMT. Point72 Asset Management L.P. increased its stake in shares of Aimmune Therapeutics by 56.4% during the second quarter. Point72 Asset Management L.P. now owns 1,688,783 shares of the biotechnology company’s stock valued at $45,411,000 after purchasing an additional 608,883 shares in the last quarter. BlackRock Inc. increased its position in shares of Aimmune Therapeutics by 18.4% during the second quarter. BlackRock Inc. now owns 3,643,840 shares of the biotechnology company’s stock valued at $97,984,000 after acquiring an additional 565,410 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Aimmune Therapeutics by 25.7% during the third quarter. Alliancebernstein L.P. now owns 1,915,689 shares of the biotechnology company’s stock valued at $52,260,000 after acquiring an additional 391,818 shares in the last quarter. GW&K Investment Management LLC bought a new stake in shares of Aimmune Therapeutics during the third quarter valued at approximately $5,079,000. Finally, C WorldWide Group Holding A S increased its position in shares of Aimmune Therapeutics by 100.1% during the second quarter. C WorldWide Group Holding A S now owns 246,749 shares of the biotechnology company’s stock valued at $6,635,000 after acquiring an additional 123,466 shares in the last quarter. 78.16% of the stock is owned by institutional investors and hedge funds.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Featured Story: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply